Open company graph database — free web & API
Login

Shionogi & Co., Ltd.

塩野義製薬株式会社Shionogi & Co.,Ltd.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
4,959
Related companies
20
§01

Basic information

BASIC
Head office
5-54, Doshomachi 5-chome, Kita-ku, Osaka 530-0011, Grand Green Osaka South Building Park Tower
Chief executive
Shunichi Tanaka
Capital
21,279,742,717  (212 100 million)
Employees (non-consolidated)
2,129 people
Employees (consolidated)
4,959 people
Start date
1948-01-01
End date
§02

Websites

2 DOMAINS
§03

Business

11
Research, development, manufacturing, and sales of pharmaceuticalsPharmaceuticalsResearch of clinical test reagents and equipmentDevelopmentManufacturingSalesDevelopment and sales of infectious disease treatmentsDevelopment and sales of antibioticsDevelopment and sales of antiviral drugsOverseas sales of pharmaceuticalsDevelopment and sales of medical devices
§04

Related companies

20 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Shionogi Business Partner Co., Ltd.
Group Alliance
Beijing Shionogi Pharmaceutical Technology Limited
Group
Shionogi B.V.
Group
Shionogi Inc.
Group
Taiwan Shionogi & Co., Ltd.
Group
Tetra Therapeutics
Group
Shionogi Smile Heart Co., Ltd.
Group Subsidiary
Shionogi Techno Advance Research Inc.
Group
Shionogi Pharma Co., Ltd.
Group
Shionogi Healthcare Co., Ltd.
Group
Shionogi Co., Ltd.
Group
Oil Japan Agro Research Co., Ltd.
Group
Yui Connection Inc.
Group Subsidiary
Qpex Biopharma, Inc.
Group Subsidiary
Torii Pharmaceutical Co., Ltd.
Group Subsidiary
HanaVax Inc.
Group Subsidiary
Shionogi Canada Inc.
Group
Stream-I Corporation
Group Subsidiary
トリイ日本橋
Group Subsidiary
AdvanSentinel
Group Subsidiary
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

128 EVENTS

Founder Saburo Shiono, established the drug wholesaler Shiono Saburo Store in Osaka Dojima-cho, selling traditional Chinese and Japanese medicinesSources

Shiro Yoshi Shiono founded the drug wholesaler "Shiono Yoshi Saburo Shoten" at 3-12 Dojima-machi, Osaka.Sources

On March 17, 1878, on his 24th birthday, he became independent and founded the drugstore "Shiono Giyoshi Saburo Shoten" at 3-12 Doshomachi, Osaka.Sources

Shifted handling items to Western medicinesSources

With the spread of Western medicine, we started importing and selling Western drugs.Sources

Initially handled mainly Japanese and Chinese medicines, but in 1886, eight years after opening, Western medicine began to spread widely, and imported Western medicines sales started.Sources

Started direct dealings with trading companies in Europe and AmericaSources

Manufactured and sold the first original drug, antacidSources

Second son Chojuro began trial manufacturing of antacid and commercialized the gastrointestinal antacid "Antachidin".Sources

Registered the trademark of the symbol of trust and confidence, the balance weight mark.Sources

Manufacture and sale of the first original new drug antacid "Antachidin": Trademark registration of the balance weight mark.Sources

Following the graduation of Giyosaburo's second son, Chojuro, from the Department of Pharmacy at Tokyo Imperial University, SHIONOGI began full-scale pharmaceutical research. During this period, the pharmacist managing Shiono Giyoshi Saburo Shoten heard from a pediatrician at Osaka Medical College (now Osaka University School of Medicine) that prescriptions for antacids were written in German medical books. Chojuro then started trial manufacturing of the antacid and succeeded in productization. This gastrointestinal antacid "Antachiden" became the first new drug developed in-house by Shiono Giyoshi Saburo Shoten.Sources

The symbol of SHIONOGI is derived from the "counterweight" used when weighing medicines on a balance. The counterweight symbolizes "accuracy," "honesty," and "trust," representing SHIONOGI's constant pursuit of precision.Sources

Shiono Pharmaceutical Plant (Fukushima-ku, Osaka City) was builtSources

Built a pharmaceutical factory "Shiono Pharmaceutical Co., Ltd." in Nishinari District, Osaka Prefecture, and fully launched the pharmaceutical business.Sources

Giyosaburo aimed to develop the business of new drug manufacturing seriously, and built a pharmaceutical factory "Shiono Seiyakujo" in Nishinari District, Osaka Prefecture (now Fukushima Ward, Osaka City).Sources

With the cooperation of Dr. Heizo Kondo, launched the heart medicine "Digatamin".Sources

It was launched as a new cardiac drug "Jigitamin" in 1912.Sources

Shiono Saburo Store merged with Shiono Pharmaceutical Plant, reorganized into Shiono Pharmaceutical Co., Ltd.Sources

Merged Shiono Yoshiro Shop and Shiono Pharmaceutical Co., Ltd., and established "Shiono Yoshiro Corporation".Sources

In 1919, aiming for further development of SHIONOGI, Giyosaburo's eldest son, Shotaro, managed the drugstore and Shiono Giyoshi Saburo Shoten, and his second son, Chojuro, managed the pharmaceutical business and Shiono Seiyakujo, merged to establish "Shiono Giyoshi Shoten Co., Ltd."Sources

Kusatsu Factory (Amagasaki City, Hyogo Prefecture) was established, with a laboratory set up inside the factorySources

Launched the Kuse Factory (Amagasaki City, Hyogo Prefecture) (currently Kuse Business Office), and established a laboratory within the factory.Sources

Built a new headquarters building in Doshomachi, Osaka CitySources

Changed company name to Shiono Pharmaceutical Co., Ltd.Sources

Sources

In 1943, the company name was changed to "Shiono Giyoshi Pharmaceutical Co., Ltd." to clearly indicate the focus on pharmaceuticals.Sources

Due to post-war inflation and economic turmoil, management deteriorated, and Gizoro indicated policies for management improvement.Sources

After the war, rapid inflation, soaring prices, and societal chaos led to the freezing of corporate deposits and termination of wartime compensation, causing SHIONOGI to nearly go bankrupt and fall into its worst management condition since its founding.Sources

Established Yuhi Farm (Shiga Prefecture) (Current: Yuhi Business Office)Sources

Listed on the Tokyo and Osaka Stock ExchangesSources

Launched painkiller "Sedes"Sources

Sources

Launched comprehensive vitamin supplement "Popon S"Sources

Sources

Launched the comprehensive vitamin supplement "Popon S".Sources

Formulation of basic policySources

Inherited a corporate culture that emphasizes manufacturing better products and technological development.Sources

In 1957, established "Basic Policy of SHIONOGI".Sources

Discovery of Shinomin, establishment of Detaillman systemSources

Discovery of Shinomin: Established the Detailman system.Sources

Declaration of Detail Man: From Proper to Detail ManSources

Launched Sulfa drug "Shinomin"Sources

In 1959, launched "Shinomin," the first sulfa drug synthesized at SHIONOGI's research institute.Sources

Constructed Central Research Institute (Fukushima-ku, Osaka) (now consolidated into Pharmaceutical Research Center)Sources

Established Animal Pharmaceuticals Department (transferred in 2002), Plant Pharmaceuticals Department (transferred in 2001), began operations of Clinical Testing Laboratory (transferred in 2002), established Taiwan Shionogi Pharmaceutical Co., Ltd.Sources

Established the Animal Medicine Department (transferred in 2002), Plant Medicine Department (transferred in 2001), and started operations of the Clinical Laboratory (transferred in 2002): Established Taiwan Shiono Yoshiro Pharmaceutical Co., Ltd.Sources

Start of broadcast of "Shionogi Music Fair" program sponsored by one companySources

Constructed Settsu Factory (Settsu City, Osaka Prefecture)Sources

Established Nichia Pharmaceutical Industry Co., Ltd. (now Shionogi Pharma Co., Ltd.)Sources

Constructed Shionogi Shibuya Building (Shibuya-ku, Tokyo), built New Drug Research Institute (Toyonaka City, Osaka Prefecture) (now Pharmaceutical Research Center)Sources

Built Shiono Yoshi Shibuya Building (Shibuya-ku, Tokyo): Built New Drug Research Institute (Toyonaka City, Osaka) (currently Medical Research Center).Sources

Launched Oxas Cefem Antibiotic "Shiomarin"Sources

Sources

In 1982, launched "Shiomarin," the world's first oxacefem antibiotic, as a self-developed product.Sources

Constructed Kanegasaki Factory (Iwate Prefecture)Sources

Construction of Kanegasaki FactorySources

Constructed Medical Science Research Institute (within Settsu Factory grounds) (now consolidated into Pharmaceutical Research Center), launched FurmarinSources

Construction of the Medical Science Research Institute (within the Settsu Factory site) (now consolidated into the Pharmaceutical Research Center): Launch of Oxas Cefem Antibiotic "Furmarin"Sources

Established Shionogi General Service Co., Ltd. (now Shionogi Business Partner Co., Ltd.), acquired capsule business from Eli Lilly (sold in 2005)Sources

Establishment of Shionogi General Service Co., Ltd. (now Shionogi Business Partner Co., Ltd.): Acquisition of capsule business from Eli Lilly & Co. (sold in 2005)Sources

Constructed new headquarters building (Doshomachi, Osaka City)Sources

Launched Cephalosporin Antibiotic "Froximox"Sources

Formulated Shionogi Action Charter (revised in 2012), launched Omori Pharmaceutical Co., Ltd. (sold in 2002), established Bushu Pharmaceutical Co., Ltd. (sold in 2010)Sources

Formulation of Shionogi Action Charter (revised in 2012): Establishment of Omori Pharmaceutical Co., Ltd. (sold in 2002): Establishment of Bushu Pharmaceutical Co., Ltd. (sold in 2010)Sources

Adoption of the Shionogi Action CharterSources

Start of the First Mid-term Management PlanSources

Transferred plant medicines, animal medicines, and pharmaceutical wholesale to other companies, consolidating into the pharmaceutical business.Sources

First Medium-Term Management Plan – Foundation Building –Sources

Established Shionogi USA, Inc., and Shionogi-GlaxoSmithKline Pharmaceuticals LLC, and began joint research on HIV treatmentsSources

Established a development subsidiary in the United States.Sources

Establishment of Shionogi USA, Inc. (now Shionogi Inc.): Overseas JV: Establishment of Shionogi-GlaxoSmithKline Pharmaceuticals LLC (later Shionogi-ViiV Healthcare LLC), initiating joint research and development of HIV infection drugsSources

Establishment of a development subsidiary in the United StatesSources

Launch of the cancer pain treatment drug "OxyContin"Sources

Crestrol has been sold in the United States and more than 100 countries worldwide since 2003Sources

Start of the Second Mid-term Management Plan, launch of the high cholesterol treatment drug "Crestor", launch of the carbapenem antibiotic "Fynvax"Sources

Start of the second medium-term management plan: Launch of cholesterol-lowering drug "Crestor": Launch of carbapenem antibiotic "Finibax"Sources

Second Medium-Term Management Plan – Momentum toward a Leap –Sources

Established Shionogi Analysis Center Inc., launched the cancer pain treatment powder "Okinom"Sources

Establishment of Shionogi Analysis Center Co., Ltd.: Launch of cancer pain relief powder "Okinom"Sources

Acquired US-based Sciele Pharma, Inc., established a joint research facility with Hokkaido University, Shionogi Drug Discovery Innovation Center, launched the hypertension treatment drug "Irbetan", launched Diferrin, PirespaSources

Acquisition of US-based Sciele Pharma, Inc. (now Shionogi Inc.): Opening of joint research facility with Hokkaido University, Shionogi Drug Discovery Innovation Center: Launch of antihypertensive drug "Irbetan": Launch of acne treatment drug "Diferin": Launch of idiopathic pulmonary fibrosis drug "Pirespa"Sources

Acquisition of U.S. pharmaceutical company Sciele Pharma, Inc.Sources

Start of the Third Mid-term Management Plan, established Shionogi Techno-Advance Research Inc., opened PET Center with Osaka University, launched the anti-influenza drug "Lapiakta", launched the antidepressant "Simbalta"Sources

Start of the third medium-term management plan: Establishment of Shionogi Techno Advance Research Co., Ltd.: Opening of Osaka University Graduate School of Medicine PET Molecular Imaging Center: Launch of anti-influenza drug "Lapiatra": Launch of antidepressant "Simbalta"Sources

Third Medium-Term Management Plan – SONG for the Real Growth –Sources

Acquired Chinese company C&O Pharmaceutical Technology, built new research building SPRC4Sources

Acquired C&O Pharmaceutical Technology (Holdings) Limited, a Chinese pharmaceutical company.Sources

Acquisition of Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited: Construction of new research building SPRC4 within the Pharmaceutical Research Center (SPRC), consolidating drug discovery research functionsSources

Construction of the new SPRC4 research facility in Toyonaka City, Osaka PrefectureSources

Restart as Shionogi Inc.Sources

Acquisition of Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) LimitedSources

Established Shionogi Limited (UK), launched HIV treatment drug "Ofikast", launched hypertension treatment drug "Aimix", contracted with Vibe HealthcareSources

Established Shionogi Limited, a development subsidiary in the UK.Sources

Establishment of European subsidiary Shionogi Limited (UK): Signing of new framework agreement with Veev Healthcare for HIV infection drugs: Launch of cancer pain relief injection "OkiFast": Launch of antihypertensive drug "Aimix"Sources

Establishment of a development subsidiary, Shionogi Limited, in the United KingdomSources

Established Beijing Shionogi Pharmaceutical Technology Co., Ltd. and Shionogi Singapore Pte. Ltd., changed royalty contract for Crestor, launched postmenopausal vaginal atrophy treatment "Osphena" in the US, launched ItratraSources

Establishment of Beijing Shionogi Pharmaceutical Technology Co., Ltd. (China): Establishment of Shionogi Singapore Pte. Ltd.: Modification of royalty agreement for Crestor with AstraZeneca: Launch of postmenopausal vaginal atrophy treatment "Osphena" in the US: Launch of antihypertensive drug "Ilutra"Sources

Launch of SHIONOGI Group's first global new drug, Osfina, in the United StatesSources

Start of Shionogi Growth Strategy 2020 (SGS2020), launched HIV treatment drug "Tebekai"Sources

Start of the medium-term management plan "Shionogi Growth Strategy 2020 (SGS2020)": Launch of HIV treatment drug "Tebikei"Sources

Formulated a mid-term management plan aiming for growth as a drug discovery-oriented pharmaceutical company, with ROE as an indicator.Sources

Medium-Term Management Plan – Shionogi Growth Strategy 2020 (SGS2020) –Sources

Launched HIV treatment drug "Trimek", allergen immunotherapy drug "Asitea", thrombocytopenia treatment drug "Mulpeta"Sources

Launch of HIV treatment drug "Triumeq": Launch of allergen immunotherapy drug "Asitea": Launch of thrombocytopenia treatment drug "Mulpeta"Sources

Updated SGS2020, established Shionogi Healthcare Inc., launched Crestor OD tabletsSources

Update of the medium-term management plan "SGS2020": Establishment of Shionogi Healthcare Co., Ltd.: Launch of cholesterol-lowering drug "Crestor OD Tablets"Sources

Promoted flexible business adaptation to environmental changes and focused on drug discovery.Sources

Update of the Medium-Term Management Plan SGS2020Sources

Update of the Medium-Term Management PlanSources

Established domestic group companies, launched Mesapain, Inchtunib, Symproic, Swinproic, OxyContin TR tabletsSources

Establishment of domestic group companies: Shionogi Career Development Center Co., Ltd., Shionogi Digital Science Co., Ltd., Shionogi Business Partner Co., Ltd., Shionogi Pharmacovigilance Center Co., Ltd., Shionogi Marketing Solutions Co., Ltd.: Launch of cancer pain relief agent "Mesapain": Launch of attention deficit/hyperactivity disorder treatment "Inchunibu": Launch of opioid-induced constipation treatment "Symproic" in the US: Launch of opioid-induced constipation treatment "Swinproic": Launch of sustained cancer pain treatment "OxyContin TR Tablets"Sources

Established Shionogi Pharma, established Shionogi B.V. in Europe, launched "Zofluza", launched "Mulpleta" in the US, launched "Jalka"Sources

Establishment of Shionogi Pharma Co., Ltd.: Establishment of European subsidiary Shionogi B.V.: Launch of anti-influenza drug "Zofluza": Launch of thrombocytopenia treatment "Mulpleta" in the US: Launch of anti-HIV drug "Jarlca"Sources

Established joint venture "Stream-I Co., Ltd." with M3, made UMN Pharma a subsidiary, opened training center in Amagasaki City, launched "Rizmoic" in Taiwan, launched "Shufu Xiao" in Taiwan, launched "Vibance"Sources

Establishment of joint venture with M3 Corporation "Stream Eye Co., Ltd.": Consolidation of UMN Pharma as a subsidiary: Opening of Shionogi Education and Training Center in Amagasaki City: Launch of opioid-induced constipation treatment "Rizmoic" in Europe: Launch of anti-influenza drug "Shufu Xie" in Taiwan: Launch of attention deficit/hyperactivity disorder treatment "Vibance"Sources

Start of Shionogi Transformation Strategy 2030 (STS2030), established joint venture with Ping An of China, made Tetra a subsidiary, made Nagase Pharmaceuticals a subsidiary, launched "Fetroja" and "Fetcroja" in the US and EuropeSources

Start of the medium-term management plan "Shionogi Transformation Strategy 2030 (STS2030)": Establishment of joint venture with Ping An Insurance "Ping An Shionogi Co., Ltd.": Full acquisition of Tetra Corporation in the US: Acquisition of Nagase Pharmaceuticals by Shionogi Pharma: Launch of Gram-negative bacterial infection treatment "Fetroja" in the US: Launch of Gram-negative bacterial infection treatment "Fetcroja" in EuropeSources

Continuing to promote drug discovery and global expansion, aiming for growth.Sources

Medium-Term Management Plan – Shionogi Transformation Strategy 2030 (STS2030) –Sources

Started sewage epidemiology survey service, launched "Swinproic" in TaiwanSources

Start of sewage epidemiology survey service for COVID-19: Opioid-induced constipation treatment drug "Swinproik" launched in TaiwanSources

Established AdvanSentinel Inc., established "Shionogi Infectious Disease Research Promotion Foundation", launched "Zokova"Sources

Establishment of joint venture company "AdvanSentinel Inc." with Shimadzu CorporationSources

Establishment of general incorporated foundation "Shionogi Infectious Disease Research Promotion Foundation"Sources

Building of SHIONOGI Group brand and establishment of group brand markSources

Establishment of Yui Connection Inc.Sources

Launch of COVID-19 treatment drug "Zocova"Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information9120001077430
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
塩野義製薬株式会社
Trade name (kana)
シオノギセイヤク
Name in English
Corporation type
301
Address
〒541-0045 大阪府大阪市中央区道修町3丁目1番8号
Postal code
5410045
Prefecture code
27
City code
128
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2019-10-08
Change date
2019-10-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
令和1年10月1日大阪市中央区道修町三丁目1番8号株式会社ピオニエ(1120001192963)を合併
Latest record
1
Excluded from search
0
Processing type
71
Correction type
0
Trade name image ID
Address image ID
Sequence number
4414321
METI gBizINFO9120001077430
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
9120001077430
Trade name
塩野義製薬株式会社
Trade name (kana)
シオノギセイヤク
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
大阪府大阪市中央区道修町3丁目1番8号
Postal code
5410045
Prefecture
大阪府
Prefecture code
27
City or district
大阪市中央区
City code
128
Street address
道修町3丁目1番8号
Organisation type
301
Processing type
71
Correction type
0
Status
Representative
代表取締役会長兼社長 CEO  手代木 功
Capital
21279000000
Employees
2808
Employees (male)
2086
Employees (female)
722
Business summary
医薬品、診断薬などの製造・販売
Website URL
http://www.shionogi.co.jp/index.html
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2019-10-08
Key information
9120001077430
§09

Sources & updates

SOURCES
↑